Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TVAX-008 in Chronic Hepatitis B
NCT07282249Phase 3Not yet recruiting
- Sponsor
- Grand Theravac Life Science (Nanjing) Co., Ltd.
- Start
- Dec 2025
- Primary completion
- Apr 2027
- Modality
- Therapeutic Vaccines
01
Overview
A Phase 3 trial of TVAX-008 in Chronic Hepatitis B (CHB), sponsored by Grand Theravac Life Science (Nanjing) Co., Ltd.. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
TVAX-008
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT07282249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282249.